Teleflex is currently evaluating Freesolve in the BIOMAG-III Pivotal Trial to support a future premarket approval application.

The Teleflex Freesolve RMS uses magnesium alloy and bioabsorbable coating technology to provide vessel support during and ...

From signing the Clergy Act to cracking down on food-aid fraud, the Trump administration had another busy week. And one of ...

This is the seventh indication application for sacituzumab tirumotecan (sac-TMT) and the second application for the ADC plus IO combination regimen of sac-TMT plus pembrolizumab accepted for ...

A newly FDA-cleared PTSD treatment uses personalized brain mapping and magnetic stimulation to target abnormal brain activity, with a clinical trial reporting a 52% reduction in symptoms and 68% ...

ArriVent BioPharma (NASDAQ:AVBP) delivered early oncology updates with initial Phase 1 results for ARR-217, an investigational antibody-drug conjugate targeting cadherin-17 (CDH17). The candidate, ...

Months after Johnson & Johnson proposed a $5.5 billion resolution of 76,000 ovarian cancer lawsuits in the United States, ...

A live webcast of the investor conference call will be available online at the investor relations page of the Company’s website at ir.cvrx.com. To listen to the conference call on your telephone, ...

Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation (BDD) ...

A pooled analysis from the global SCORPIO clinical program showed potent antiviral activity with ensitrelvir across age, vaccination status and risk for severe disease New data underscores that even ...

The US FDA has approved GSK’s Hibsago for chronic hepatitis B, with 19% of trial participants achieving a functional cure.